Translational Research

font decreasefont increase SocialTwist Tell-a-Friend

Overview

NIH quotes “Translation research (TR) includes two major areas in coherence. One is the process of applying discoveries generated during research in the laboratory and in preclinical studies, to the development of trials and studies in humans. The second area of translation concerns, research aimed at enhancing the adoption of best practices in the community.


Translation may seem like the end product of research and medical practice, but in the real sense, is the major fumbling block of science, and medicine. We believe that advancement in TR depends on integration of technology, research, and hospital components. The aforementioned trio allows conceptualization of a research idea into a clinically viable product, producing substantial benefit to the scientific community and society as a whole. We at AHERF have created a sustainable ecosystem for conducting TR through synergizing the above components on a common platform.


AHERF houses several facilities of scientific, clinical and technology support not only to its own researchers but also to the wider hospital community and to various technology driven incubate companies in its premises.


Basic Research

Strategic Focus

CMBRC aims to carry out research in the areas of cell, molecular biology, and immunology. A major thrust area is development of circulatory biomarkers for clinical and biotechnology applications.


Cell & Molecular Biology Research Center (CMBRC):

Constructed in 4000 sq.ft. of space, with 2000 sq.ft. converted to a Class 10,000 cell culture facility. The facility is equipped with state of art infrastructure to pursue itsresearch interests:

  • Cell and molecular biology research
  • Circulatory biomarkers discovery and development
  • Molecular and immune diagnostics

Current research activities:

In line with the first area of translation; “bench to bedside”, we established the circulating biomarker platforms, i.e. exosomes and circulatory cell-free DNA. These platforms could potentially by-pass the need of tissue biopsy for offering precise, non-invasive molecular and proteomic diagnostics for patient stratification, targeted therapy, prognosis, diagnosis, and therapy monitoring. We successfully utilized the exosome platform to establishthe diagnosis of high-grade gliomas. Currently, the exosome platform is being extended to various deep-rooted cancers and other pathological conditions.


Our portfolio of circulatory biomarker based translational research includes different deep-rooted cancers i.e. prostate, breast, ovarian, etc., various cardiovascular dysfunctions, diabetes and organ transplantation related complications. We would also like to foray our expertise in development of therapeutic applications of exosomes.


Our Scientific Team

Dr. Manda Venkata Sasidhar, Chief Scientist; AHERF and other research scientists.


Our Clinical Team

We have identified active consortium of research-oriented clinicians for our biomarker discovery and development program. Some of our important clinicians include

Dr. Amitva Ray, Sr. Neurologist; Apollo Hospital, Hyderabad

Dr. Sanjay Maitra, Sr. Nephrologist; Apollo Hospital, Hyderabad

Dr. M. Somasekhar, Sr. Nephrologist; Apollo Hospital, Hyderabad


Collaboration

Collaborations are a key focus of our culture, and our research-working model. We are establishing partnerships with a broad range of organizations, and institutions to help advance the application and potential of our established technology platforms. Some of the potential applications of the circulatory biomarker program are drug discovery and development, patient stratification in clinical trials, noninvasive drug monitoring, exploring disease, and drug mechanism of action and drug delivery.
We are aiming at collaborations with biotech and pharma companies to help them use our various circulatory biomarker based programs to enhance their drug development programs, and R&D programs.

  • About the Project: To study the presence of endothelial cells in the blood samples of patients with Poly Cystic Ovarian Syndrome (PCOS), molecular characterization of the Endothelial Progenitor Cells (EPC) as a predictive marker for cardiovascular diseases is carried out by AHERF in collaboration with IIT Madras.
  • Status: The first phase of identification of EPCs is completed and second phase in which the characterization has to be evaluated is approved by the Ethics Committee and is awaiting funding applied to AHERF.
  • About the Project: To study the presence of endothelial cells in the blood samples of patients with Poly Cystic Ovarian Syndrome (PCOS), molecular characterization of the Endothelial Progenitor Cells (EPC) as a predictive marker for cardiovascular diseases is carried out by AHERF in collaboration with IIT Madras.
  • Status: The first phase of identification of EPCs is completed and second phase in which the characterization has to be evaluated is approved by the Ethics Committee and is awaiting funding applied to AHERF.
  • About the Project: A multi centric study to interpret various laboratory tests to identify disease states . To interpret these tests and to differentiate normal values from abnormal values, reference intervals are used. The observed laboratory value is compared to the reference range to make clinical and meaningful decisions.
  • Objectives:
    • To identify 95% reference interval for haematological and biochemical parameters.
    • Partitioning of the data for age, sex and recommend separate reference interval if significantly different.
    • To study regional difference, if any for these laboratory parameters.
  • Status: Study Completed
  • Results: Haemoglobin was less for the males and more so for the females.The low platelet count came in as a surprise. This findings has very important clinical implications as persons with platelet counts of 1,10,000 - 1,30,000 are subject to several investigations.Gender based partitioning is required for haemoglobin, packed cell volume, ESR, high density lipoprotein (HDL), triglycerides, serum creatinine, serum uric acid, ALT and GGTP. Age based reference intervals for ESR need to be considered.
  • Click here to download the project report.
  • Click here to download the project report.
  • Click here to download the project report.
  • Click here to download the project report.
 
 
Achieving critical yet most effective, affordable and far reaching healthcare capabilities through Research & Education. Full time and part time Clinical Research Courses successfully running at different sites.